Format

Send to

Choose Destination
Trends Microbiol. 2015 Oct;23(10):653-665. doi: 10.1016/j.tim.2015.07.005.

Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents?

Author information

1
Equipe Labellisée par la Ligue contre le Cancer - Institut de Génétique Moléculaire de Montpellier, UMR 5535 CNRS, 1919 route de Mende, 34293 Montpellier cedex 5, Université de Montpellier, 163 rue Auguste Broussonnet, 34090 Montpellier, France. Electronic address: mireia.pelegrin@igmm.cnrs.fr.
2
Equipe Labellisée par la Ligue contre le Cancer - Institut de Génétique Moléculaire de Montpellier, UMR 5535 CNRS, 1919 route de Mende, 34293 Montpellier cedex 5, Université de Montpellier, 163 rue Auguste Broussonnet, 34090 Montpellier, France.

Abstract

Monoclonal antibodies (mAbs) are increasingly being considered as agents to fight severe viral diseases. So far, they have essentially been selected and used on the basis of their virus-neutralizing activity and/or cell-killing activity to blunt viral propagation via direct mechanisms. There is, however, accumulating evidence that they can also induce long-lasting protective antiviral immunity by recruiting the endogenous immune system of infected individuals during the period of immunotherapy. Exploiting this property may revolutionize antiviral mAb-based immunotherapies, with benefits for both patients and healthcare systems.

KEYWORDS:

Fc receptors; antiviral therapy; immune complexes; immunotherapy; monoclonal antibodies; vaccine-like effects

PMID:
26433697
DOI:
10.1016/j.tim.2015.07.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center